Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 904-551-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing adsorption, distribution, metabolisation and excretion of the substance. Based on mainly physico-chemical parameters the substance is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Toxico-kinetic information on Hexalon
Introduction
The test material Hexalon (CAS #79-78-7) is a trimethyl-cyclohexene with an alkyl chain to it. The alkyl chain has an alpha-beta conjugated ketone bond and has an allyl bond at the end of the chain (see section 1 on identity). Hexalon is a liquid with a melting point of < -20 °C and a boiling point of 301.1 °C under atmospheric pressure. The substance has a molecular weight of 232 g/mol and a water solubility of 79.0 mg/L at 24°C. Hexalon has a Log Kow of 5.5 at 24°C and a vapour pressure of 0.08 Pa at 24°C. The substance contains no hydrolysable groups and no hydrolysis is anticipated. Experimental information on hydrolysis is not available.
Absorption
Oral route: There is an acute oral study in mice showing an LD50 of 9500 mg/kg bw indicating some oral absorption. Oral absorption is also anticipated based on the effects seen in a repeated dose toxicity test with the analogue Galbascone (alpha-hydrocarbon nephropathy and bladder effects). The relatively low molecular weight (232 g/mol) and the moderate octanol/water partition coefficient (Log Kow 5.5) and water solubility (79.0 mg/L) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This shows that Hexalon is likely to be absorbed orally and therefore the oral absorption is expected to be > 50%.
Dermal route: Based on the physico-chemical characteristics of the substance, being a liquid, its molecular weight (232), log Kow (5.5) and water solubility (79.0 mg/L), indicate that some dermal absorption is likely to occur. The optimal MW and log Kow for dermal absorption is < 100 g/mol and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). Hexalon is outside optimal range and therefore the skin absorption is expected to be <=50%.
Inhalation route: Absorption via the lungs is also indicated based on these physico-chemical properties. Though the inhalation exposure route is thought to be minor, because of its low volatility (0.08 Pa), the octanol/water partition coefficient (5.5), indicates that inhalation absorption is possible. The blood/air (B/A) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. 2012 have developed B/A portioning model for humans using the most important and readily available parameters:
Log PBA = 6.96 – 1.04 Log (VP) – 0.533 (Log) Kow – 0.00495 MW.
For Hexalon the B/A partition coefficient would result in:
Log P (BA) = 6.96 – 1.04 x -1.097 – 0.533 x 5.5 – 0.00495 x 232 = 4.021
This means that Hexalon has a slight tendency to go from air into the blood. It should, however, be noted that this regression line is only valid for substances which have a vapour pressure > 100 Pa. Despite Hexalon being out of the applicability domain and the exact B/A partitioning may not be fully correct, it can be seen that the substance will be absorbed via the inhalation route and anticipated to be > 50%.
Distribution:The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. Due to the expected metabolisation the substance and the in vitro BCF study the substance would not accumulate in the body fat.
Metabolism: No studies regarding the metabolism of Hexalon are available however supporting literature is available to identify possible metabolic pathways of Hexalon. According to JECFA (1999) Hexalon can be predicted to be metabolised to innocuous products, which was confirmed by EFSA in 2014. Belsito et al. (2007) states that “the available evidence indicates that the ionones and rose ketones are extensively metabolized in vivo by pathways involving: oxidation, reduction and conjugation. These metabolites do not raise issues of toxicological concern”.
Potential metabolic products are presented in Fig. 1. Metabolites derived with the OECD Toolbox are presented in Fig. 2
Fig. 1 Hexalon and the potential sites of attack for Phase 1 metabolism
Fig. 2 Theoretical metabolites from the Rat liver S9 metabolism
simulator (OECD Toolbox , 3.3.5.17): epoxidation (1) or
hydroxylation/oxidation (3 and 4) of the double bond and reduction of
the ketone group (2)
Phase 1 metabolites can be formed based on: Reduction of the ketone group to a secondary alcohol;
Hydroxylation/oxygenation of the cyclohexene ring; Oxidation of the angular methyl groups; reduction of the double bonds in the exocyclic alkenyl side chain or cyclic portion of the molecule to form dihydro derivatives; Epoxidation of isolated (non-conjugated) double bounds of exocyclic chain and subsequent reaction with epoxide hydrolases or glutathione transferase. Phase II metabolism can include conjugation of the hydroxylated metabolites and/or epoxide metabolites.
Excretion: The urine is one of the excretion pathways of Hexalon’s metabolites based on the anticipated effects in the kidney and bladder. These are anticipated because these effects were seen in the in the repeated dose study with the analogue Galbascone. Any unabsorbed substance will be excreted via the faeces.
Discussion
Hexalon is expected to be readily absorbed, orally, via inhalation and via the skin, based on physico-chemical parameters. The MW and the log Kow are higher than the favourable range for dermal absorption but significant absorption is likely. The IGHRC (2006) document of the HSE and mentioned in the ECHA guidance Chapter 8 will be followed to derive the final absorption values for the risk characterisation.
Oral to dermal extrapolation: There are adequate data via the oral route and the critical toxic effect is related to systemic effects and therefore route to route extrapolation is applicable. The substance is absorbed orally and is likely metabolized in the liver (see metabolism paragraph). The absorption will be slower via the skin and the substance will also pass the liver. It will be assumed that the oral absorption will equal dermal absorption. The toxicity of the dermal route will therefore not be underestimated. Using the asymmetric handling of uncertainty the oral absorption will be considered 50% (though likely to be higher) and the dermal absorption will be considered also 50% (though likely to be lower).
Oral to inhalation extrapolation: Though Hexalon is not a volatile substance the inhalation exposure will be considered. In the absence of bioavailability data it is most precautionary that 100% of the inhaled vapour is bioavailable. For inhalation absorption 100% will be used for route to route extrapolation, because this will be precautionary for the inhalation route.
References
Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partition coefficient using basic physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
D. Belsito, D. Bickers, M. Bruze, P. Calow, H. Greim, J.M. Hanifin , A.E. Rogers, J.H. Saurat, I.G. Sipes, H. Tagami., 2007. toxicologic and dermatologic assessment of ionones when used as fragrance ingredientsFood and Chemical Toxicology 45 (2007) S130–S167.
European Food Safety Authority (EFSA); Scientific Opinion on Flavouring Group Evaluation 210, Revision 1 (FGE.210Rev1): Consideration of genotoxic potential for α,β-unsaturated alicyclic ketones and precursors from chemical subgroup 2.4 of FGE.19. EFSA Journal 2014;12(2):3587
IGHRC, 2006, Guidelines on route to route extrapolation of toxicity data when assessing health risks of chemicals
JECFA, 1999. Safety Evaluation of Certain Food Additives. WHO Food Additive Series 42: Ionones and structurally Related Substances. Prepared by the Fifty-first Meeting of the Joint FAO/WHO Expert Committee on Food Additives, pp. 335–352.
Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.